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INTRODUCTION
Interleukin-10 (IL-10) is a multifunctional cytokine with
diverse effects on the immune response. IL-10 limits inflam-
mation and modulates immune response by inhibiting the
production of various pro-inflammatory and Th1 cytokines
and blocking the expression of MHC class II and co-stimu-
latory molecules on the surface of antigen presenting cells
and promoting the development of regulatory T cells. On
the other hand, IL-10 is a potent cofactor for proliferation of
human B cells and affects the B cell differentiation and iso-
type switching (1).
The role of IL-10 in glomerulonephritides (GNs) has been
investigated in several studies with conflicting results. The
administration of IL-10 (2), endogenous IL-10 (3), or IL-10
gene transfer (4, 5) diminished Th1 response and attenuated
glomerular injury in murine crescentic GN initiated by a
planted antigen. IL-10 administration also inhibited passive
anti-glomerular basement membrane (GBM) GN (6) and
suppressed mesangial cell proliferation in anti-Thy 1 GN in
rats (7). More recently, adenovirus mediated IL-10 transfer
had effects on prevention of the development of glomeruloscle-
rosis in FGS/Kist mice model (8). Yin et al. (9) reported IL-
10 gene deficiency evoked more severe lupus nephritis and
higher mortality in murine lupus model. But in other exper-
iments, IL-10 administration induced mesangial cell prolif-
eration with transient reduction of creatinine clearance (10)
and had no protective effects on passive anti-GBM GN in rats
(11). Moreover, IL-10 up-regulated MHC class II expression
by rat mesangial cells (12) and anti-IL-10 antibodies admin-
istration diminished the severity of GN in ‘‘lupus-prone’’
mice (13). In human GN, increase in tubulointerstitial expres-
sion of IL-10 was accompanied by nephrotic-range protein-
uria (14). We also observed that the increased intrarenal expres-
sion of IL-10 was associated with tubular atrophy and inter-
stitial fibrosis in renal biopsies from patients with IgA neph-
ropathy (15).
The gene encoding IL-10 has been mapped to chromosome
1q and several polymorphic sites within the promoter region
have recently been described (16). Three biallelic polymor-
phisms within the IL-10 promoter region, at positions -1,082,
-819, and -592 from the transcription initiation site, have
also been identified and one of these polymorphisms, at posi-
tion-1,082 from the transcription initiation site, was shown
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Interleukin-10 Promoter Polymorphism is Associated with the 
Predisposition to the Development of IgA Nephropathy and Focal
Segmental Glomerulosclerosis in Korea
The roles of interleukin-10 (IL-10) have been emphasized in several models of glo-
merulonephritis (GN). Three biallelic polymorphisms within the IL-10 promoter region,
at positions -1,082, -819, and -592 from the transcription initiation site, were shown
to affect the level of IL-10 production. To investigate the effect of IL-10 promoter
polymorphisms on the predisposition to development of GN in Korea, IL-10 promoter
polymorphisms were assayed by polymerase chain reaction followed by restriction
fragment length polymorphism in 108 patients with IgA nephropathy (IgAN), 49 focal
segmental glomerulosclerosis (FSGS), and 100 healthy controls. In comparison with
the control, the frequency of -1,082*G alleles were lower in IgAN and the frequen-
cies of -592*C and -819*C were lower in FSGS, respectively. As for the haplotype,
GCC haplotype was less frequent among IgAN than the control and ATA haplotype
was more frequent among FSGS than the control (p<0.05). The frequency of inter-
mediate producer genotypes (GCC/ACC and GCC/ATA) were lower among IgAN
or FSGS than the control. Our findings suggested that IL-10 promoter polymorphism
predisposed to the development of IgAN and FSGS in Korean patients. 
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to affect the in vitro IL-10 protein production in peripheral
blood cells from healthy individuals (17). 
Based on the aforementioned biological effects of IL-10
and its role in GN, inter-individual differences in the levels
of IL-10 production resulting from promoter polymorphism
could influence the individual predisposition to several auto-
immune diseases, including glomerulonephritides. Increased
frequency of the GA/AA genotypes at position -1,082 of the
IL-10 promoter was reported in patients with several autoim-
mune diseases (18, 19). In fact, IL-10 promoter polymor-
phism was associated with renal involvement in southern
Chinese patients with systemic lupus erythematosus (20).
Low IL-10 producer genotype was more prevalent in Cau-
casian kidney transplant recipients than in the control pop-
ulation (21). We also observed a lower frequency of G allele
at position -1,082, denoting high IL-10 producer, in Korean
kidney transplant recipients compared with the healthy con-
trols (22). Glomerulonephritis is the most common cause of
renal failure in Korean kidney transplant recipients (23). In
addition IgA nephropathy and focal segmental glomerulo-
sclerosis is two most common glomerulonephritis leading to
end stage renal failure in Korea. It is therefore possible that
IL-10 promoter polymorphisms may be responsible for, at
least in part, a portion of the genetic predisposition to glome-
rulonephritides. The present study was undertaken to inves-
tigate the role of these 3 biallelic IL-10 promoter polymor-
phisms in Korean patients with IgA nephropathy (IgAN)
and focal segmental glomerulosclerosis (FSGS) which were
common GNs leading to the end stage renal disease and
considered to have different pathogenetic mechanism apart
from each other. 
MATERIALS AND METHODS
Patients and control subject
Patients were recruited from the Department of Internal
Medicine, Kangdong Sacred Heart Hospital, and Seoul
National University Hospital in Seoul, Korea. One hundred
and eight patients with primary IgAN and forty nine patients
with primary FSGS who provided informed consent, were
enrolled in this study. The diagnosis of IgAN and FSGS was
based on the typical light, immunofluorescent, and electron
microscopic changes on a renal biopsy. Patients with the
evidences of systemic diseases such as diabetes, chronic liver
disease, and systemic lupus erythematosus were excluded.
One hundred randomly selected subjects who had no evidence
of renal disease and were normotensive were also recruited
from the Health Promotion Center of the same hospitals as
controls. The Institutional Review Board of two institutions
approved the research protocol used for this study.
Extraction of genomic DNA and genotype determination
Genomic DNA was extracted from the buffy coat using
commercial DNA isolation kit (Qiagen, Germany). The 3
biallelic IL-10 promoter polymorphisms were detected by
PCR amplification followed by restriction enzyme digestion
basically as described previously (24). Briefly, the DNA frag-
ment containing the position -592 was amplified in 50  L
reaction mixture containing 500 ng of template DNA, 0.5
M of of each primer, 1.5 mM of MgCl2, 200  M each of
dGTP, dATP, dTTP and dCTP, 2.5 unit of Taq polymerase
(Promega, Medison WI, U.S.A.) and Taq polymerase buffer.
Amplification of the fragment around -592 was performed
under the same condition except that a final concentration of
2 mM MgCl2 was used. Amplification of fragment around
-1,082 was performed using HotStarTaq kit (Qiagen, Ger-
many), and Q-solution was included in the PCR reaction
mixture. Primers used were as follows: for the amplification
of -592 fragment, sense primer 5′ gtgttcctaggtcacagtga, anti-
sense primer 5′gtcatggtgagcactacctga 3′ ; for -819, sense
primer 5′ tcattctatgtgctggagatg 3′ , antisense primer 5′ tgg-
gggaagtgggtaagagt 3′ ; for -1,082, sense primer 5′ ctcgctg-
caacccaactggc 3′ , antisense primer 5′tcttacgcaacccaactggc
3′ . PCR was performed using Perkin Elmer Cetus thermo-
cycler under the following cycling parameters: denaturation
at 94℃ for 2 min, followed by 35 cycles of denaturation at
94℃ for 30 sec; annealing at 60℃ for 45 sec; and extension
at 72℃ for 1 min. This was followed by final extension at
72℃ for 10 min. For amplification of the -1,082, an initial
activation step of 95℃ for 15 min preceded the cycling pro-
gram. The two alleles at each polymorphic site was identi-
fied by incubating 15  L aliquot of the PCR product with
specific restriction enzyme, followed by electrophoresis on 3%
agarose gels. Restriction enzyme RsaI cut the fragment at
the position -592 when allele A was present, giving rise to
176 and 236 bp fragments. In the presence of allele C in -819
fragment, 125 and 84 bp fragments were generated by diges-
tion with MaeIII. Mnl I cut -1082 fragment when allele G
was present to generate 106 and 33 bp fragments. The results
of this restriction fragment length polymorphism assay were
confirmed by direct sequencing of the promoter region of
the IL-10 gene in 10% of patients and controls (Macrogen
Inc., Seoul, Korea).
Statistical analysis
All data were analyzed using the SPSS version 10.0. The
chi-square test was used for detecting differences in the geno-
type distribution of the patients and controls. Odd ratio for
individuals with a specific genotype to develop GN was esti-
mated by Mantel-Haenszel test. A p-value that was less than
0.05 was considered to be statistically significant.RESULTS
Allele frequencies of IL-10 promoter 
Frequencies of the alleles of IL-10 promoter in our patients
and controls were summarized in Table 1. For comparison,
reported allele frequencies from southern Chinese (20) and
U.K. white population (25) were also included. The polymor-
phisms at -592 and -819 bp were found to be in complete
linkage disequilibrium. This meant that individuals with A
allele at -592 bp also had T allele at -819 bp, whereas those
with C allele at -592 bp also had C allele at -819 bp. The
allele frequencies of our controls were very similar to those
of Chinese population but markedly different from U.K.
population. To point out, the frequency of G allele at posi-
tion -1,082 was markedly lower among our controls than the
U.K. population. 
For IgAN patients, the frequency of G allele at position
-1,082 was even significantly lower than the control (p=0.006).
For FSGS, the frequency of C allele at position -592 or at posi-
tion -819 was significantly lower than the control (p=0.026). 
Haplotype frequencies of IL-10 promoter 
Three haplotypes were identified: GCC, ACC and ATA
for the -1,082, -819 and -592 polymorphisms, respectively.
The frequencies of the haplotypes of IL-10 promoter in IgAN,
FSGS patients and controls were summarized in Table 2, 3.
There was a statistically significant difference in the fre-
quency of GCC haplotype between IgAN and control. That
is, IgAN patients were less likely to carry GCC haplotype
than normal controls (0.028 vs. 0.095, p=0.006). FSGS patients
were less likely to carry GCC haplotype than controls, although
this did not reach a statistical significance (0.031 vs. 0.095).
Besides, FSGS patients had a higher frequency of ATA hap-
lotype than normal control (0.755 vs. 0.620, p=0.026) 
Genotype frequencies of IL-10 promoter
From our subjects, we observed five genotypic combina-
tions of the three haplotypes: GCC/ACC, GCC/ATA, ACC/
ACC, ACC/ATA and ATA/ATA. No GCC homozygous sub-
jects were observed from our study (Table 4).
No patients among the IgAN and FSGS group carried
GCC/ACC genotype, while 8 (8%) among normal control
group carried this genotype. This marked a statistical differ-
ence either between IgAN and control (p=0.002) or between
FSGS and control group (p=0.049). There was no significant
difference in the frequency of GCC/ATA genotype either bet-
ween IgAN and control group or between FSGS and control
group. However, as for the genotypic frequency of interme-
diate producer as a whole (i.e., GCC/ACC and GCC/ATA
genotypes), there was a significant difference either between
IgAN and control (p=0.005) or between FSGS and control
group (p=0.048). 
DISCUSSION
Three biallelic polymorphisms at positions -1,082(G/A),
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Alleles IgAN FSGS Controls
Chinese
(20)
U.K.
(25) 
-592*A 0.70 0.76* 0.62 0.67 0.21
-592*C 0.30 0.24* 0.38 0.33 0.79
-819*T 0.70 0.76* 0.62 0.67 0.21
-819*C 0.30 0.24* 0.38 0.33 0.79
-1,082*G 0.03
� 0.03 0.09 0.06 0.51
-1,082*A 0.97
� 0.97 0.91 0.94 0.49
Table 1. Allele frequencies of the interleukin-10 promoter region
among Korean patients and controls and southern Chinese and
U.K. white population 
*p=0.026 vs. control, 
� p=0.006 vs. control.
Genotype
IgAN
(n=108)
FSGS
(n=49)
Controls
(n=100)
GCC/ACC 0 (0%)* 0 (0%)
� 8 (8%)
GCC/ATA 6 (5.6%) 3 (6.1%) 11 (11%)
ATA/ATA 52 (48.1%) 28 (57.1%) 41 (41%)
ATA/ACC 42 (38.9%) 15 (30.6%) 31 (31%)
ACC/ACC 8 (7.4%) 3 (6.1%) 9 (9%)
GCC heterozygote 6 (5.6%)
� 3 (6.1%)
� 19 (19%)
(GCC/ACC or 
GCC/ATA)
Table 4. IL-10 genotype frequencies in healthy controls, IgAN
and FSGS
*p=0.002 vs. healthy control, 
�
p=0.049 vs. healthy control, 
�
p=0.005 vs.
healthy control, 
�
p=0.048 vs. healthy control.
Haplotype IgAN
Healthy
control
Odds Ratio
(95% CI)
GCC 0.028* 0.095 0.27 (0.11-0.70)
ACC 0.269 0.285 0.92 (0.59-1.42)
ATA 0.704 0.620 1.46 (0.97-2.20)
Table 2. Haplotype distribution of IL-10 promoter gene in IgAN
patients and healthy control
*p=0.006 vs. healthy controls.
Haplotype FSGS
Healthy
control
Odds ratio
(95% CI)
GCC 0.031 0.095 0.30 (0.08-1.04)
ACC 0.214 0.285 0.68 (0.39-1.21)
ATA 0.755* 0.620 1.89 (1.09-3.25)
Table 3. Haplotype distribution of IL-10 promoter gene in FSGS
patients and healthy control
*p=0.026 vs. healthy controls.992 H.J. Chin, K.Y. Na, S.J. Kim, et al.
-819 (A/T) and -592 (A/C) of IL-10 promoter region are gen-
erally known to produce three haplotypes: GCC, ATA and
ACC. Such allelic or haplotypic difference correlated with
the difference in in vitro IL-10 production after various immu-
nological stimuli. Even though not confirmed in recent study
(26), Turner et al. reported that the presence of -1,082*A
allele was associated with lower production of IL-10 by mito-
gen-stimulated peripheral blood leukocyte (17). In addition,
the -592*A allele was associated with a reduced IL-10 pro-
duction by peripheral blood mononuclear cell in the pres-
ence of IFN- (27). Some authors classify IL-10 haplotypic
variations into high, intermediate and low producers (28,
29). GCC homozygous patients were considered as high
producers (i.e., GCC/GCC genotype), GCC heterozygous
patients as intermediate producers (i.e., GCC/ACC and GCC/
ATA genotypes) and GCC negative patients as low producers
(i.e., ATA/ATA, ACC/ATA and ACC/ACC genotypes)
In this study, we analyzed the polymorphic frequencies of
the IL-10 promoter regions in Korean patients with IgAN
and FSGS. We found that the distribution of alleles of IL-10
promoter in Korean healthy population is very similar to
those in southern China population, but markedly different
from Caucasian, which is consistent with the previous reports
(17, 20, 24, 25). Characteristically, none of our controls and
patients have the -1082*GG genotype or GCC/GCC geno-
type. This might mean that there was no one with ‘‘high IL-
10 producing’’ phenotype among our subjects-either among
the GN patients or among the healthy control. 
The frequencies of -1,082*G alleles, which were reported
to be related with a higher IL-10 production (17, 28, 27),
were lower in patients with IgAN than healthy controls. The
frequencies of -819*C and -592*C, which are also known
to represent a high producer, were also lower among FSGS
than the control (Table 1). 
With respect to the haplotypes (Table 2, 3), there was a
lower frequency of GCC haplotype among IgAN patients
than the control (p=0.006, OR=0.27, CI [0.11-0.70]). FSGS
patients were also less likely to carry the GCC haplotype,
although not reached a statistical significance. ATA haplo-
type, which is known to represent a low producer, was more
frequent among FSGS than control (p=0.026, OR=1.89, CI
[1.09-3.25]).
Such genetic difference is more pronounced in terms of
the genotype (Table 4). None of our IgAN or FSGS group
carried the GCC/ACC genotype, which marked a stark dif-
ference in comparison with the control group with 8% fre-
quency of the GCC/ACC genotype. Such statistical differ-
ence still holds in terms of the intermediate producer group,
GCC/ACC and GCC/ATA genotypes, as a whole. Collectively,
these findings might mean that the lower level of IL-10 pro-
duction resulting from IL-10 promoter polymorphism pre-
disposes individuals to the development of IgAN and FSGS.
Our findings are very similar to the study of Mok et al. (20)
who demonstrated lower frequencies of -579*CC/-824*CC
genotype and non-ATA haplotype in SLE patients with renal
involvement. It was very interesting to note that IL-10 pro-
moter polymorphisms predispose individuals to 3 different
GNs, IgAN, FSGS, and lupus nephritis, which have an inde-
pendent immunological pathogenesis. In addition, the fre-
quency of -1,082*AA genotype was more prevalent in Cau-
cacian kidney transplant recipient than in control group (21).
In our 185 kidney transplant recipients, the frequencies of -
592*CC/-819*CC and -1082*GA genotype were 9.2% and
5.9% respectively, which were lower than in controls (22). In
this regard, it might be worthwhile to investigate the role
of IL-10 promoter polymorphism in other nephropathies such
as membranous GN, membranoproliferative GN and even
diabetic nephropathy which are common causes of end stage
renal disease.
The biological effects of IL-10 and the role of IL-10 in GN
is very complex and is beyond the scope of our discussion.
From the results of the present study, it may be speculative
that IL-10 limits inflammation and modulates injuries to
kidney initiated by various different mechanisms. In this
respect, IL-10 may play an important role in the process of
progression common to both IgA nephropathy and FSGS.
Recently IL-10 high producer genotype was reported to be
associated with slower progression of IgA nephropathy and
FSGS in Caucasian patients (30). Because our study was a
cross-sectional study with a great variability in follow-up
duration and patient characteristics affecting the progression
of glomerulonephritis, we could not analysis the association
of IL-10 gene polymorphism and progression of diseases.
Well-designed prospective long-term study will be necessary
to evaluate the role of IL-10 in the progression of various
primary and secondary glomerular diseases having different
mechanisms of pathogenesis such as IgA nephroapthy, FSGS,
membranous nephropathy, lupus nephritis, and diabetic ne-
phropathy. 
Finally, a cytokine works in the context of ‘‘networks of
cytokines’’ i.e. many cytokines influence each other. The role
of gene polymorphisms of various cytokines other than IL-
10 in GN has been reported (31-33) and allelic distributions
in cytokine gene polymorphisms varied according to the eth-
nic groups (25). In this context, it might be necessary to
examine our observation as to the effect of IL-10 promoter
gene polymorphism on the development of GN in different
ethnic populations.
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